HOME >> BIOLOGY >> NEWS
Columbia University launches multi-year campaign to support stem cell research

NEW YORK, NY, June 15, 2005 Columbia University Medical Center (CUMC) announced today that it is halfway toward realizing the first phase of a multi-year campaign to build upon the university's groundbreaking stem cell research and lead the effort to fully realize the therapeutic potential of stem cells. Of the $50 million goal for the first stage of the campaign, $25 million has been raised from the private sector, specifically for diabetes and neural stem cell research.

Columbia University Medical Center researchers are at the forefront of an extraordinary movement to revolutionize medical approaches to therapeutics through its Stem Cell Initiative. Columbia's leadership in developmental biology, neuroscience research, transplantation, and cell replacement therapy uniquely positions the university to push stem cell research forward, and more than 40 CUMC researchers are currently conducting leading stem cell studies.

"This initiative will provide our researchers with the resources necessary to fully realize the potential of stem cells," said Gerald D. Fischbach, M.D., executive vice president of Columbia University Medical Center and dean of the faculty of medicine at Columbia's College of Physicians and Surgeons. "Columbia continues to be a leader in this revolutionary health technology that holds the promise to benefit people suffering from a wide variety of debilitating health problems."

Federal restrictions on human embryonic stem cell research funding and lagging state funds have limited available government support for this emerging and promising research, prompting CUMC to reach out to the private sector with this crucial stem cell initiative.

CUMC researchers are currently exploring the vast potential of stem cells to treat a wide range of illnesses, including Parkinson's disease, amyotrophic lateral sclerosis (ALS), diabetes, pancreatic cancer, leukemia, stroke and other diseases of the nervous system, liver, eye,
'"/>

Contact: Craig LeMoult
cel2113@columbia.edu
212-305-0820
Columbia University Medical Center
15-Jun-2005


Page: 1 2 3

Related biology news :

1. Columbia University Medical Center awarded $3 million to drive Alzheimers genetics research
2. Columbia scientists determine 3-dimensional structure of cells fuel gauge
3. Columbia University licenses next-generation DNA sequencing technology
4. New bird discovered on unexplored Columbian mountain
5. Columbia University Medical Center receives major new NIH Clinical Science investment funds
6. Columbia University awards 2006 Horwitz Prize to biologist who explained gene transcription
7. Columbia University receives $16.9 million NIEHS award to study arsenic in ground water
8. Contaminants linked to sturgeon decline in Columbia river
9. Columbia University Medical Center researchers discover potential mechanism for tumor growth
10. UF, Columbia scientists closer to new cancer detection method
11. Columbia University awards 2005 Horwitz Prize to Israeli structural biologist

Post Your Comments:
(Date:8/25/2015)... LAKE CITY and BELLEVUE, Wash. ... global leader in advanced robotic systems, announced today it ... robotic unmanned ground vehicle (UGV), at the National Tactical ... City.  The Guardian S is the ... the culmination of years of research and in-field trials ...
(Date:8/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Card Alliance and the EMV Migration Forum.  ... Card Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. ... leaders promoting adoption of smart card technology. ...
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
(Date:9/2/2015)... , Sep. 02, 2015 ... announced the addition of Jain PharmaBiotech,s new report ... to their offering. This report follows ... characteristic that can be objectively measured and evaluated ... processes as well as pharmacological responses to a ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, Inc., ... in the multicenter Phase 2 clinical trial of ... treatment of recurrent subfoveal choroidal neovascularization secondary to ... a unique vascular endothelial growth factor (VEGF) receptor ... "This landmark proof-of-concept study will evaluate ...
(Date:9/2/2015)... , September 2, 2015 BiondVax ... of the National Institute of Allergy and Infectious Diseases (NIAID), ... the Department of Health and Human Services (HHS), to launch ... the United States in the 2015-16 timeframe. ... vaccine candidate, Multimeric-001 (M-001), as a primer vaccine, which would ...
(Date:9/2/2015)... ... September 02, 2015 , ... The ... creating professional commercial video content, to analysis of athletic performance. Producing high-resolution ... go by too quickly to process with the naked eye. , Slow ...
Breaking Biology Technology:Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3
Cached News: